Rituximab and other anti-B-cell agents in immune-mediated inflammatory rheumatic diseases

Nasonov, E.; Lila, Azmi M

doi:10.32756/0869-5490-2019-1-7-17

Cited by 3 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Постоянно расширяющийся перечень ГИБП включает моноклональные антитела (мАТ) к различным детерминантам иммунокомпетентных клеток или цитокинам и гибридные белковые молекулы, ингибирующие активность цитокинов или взаимодействие Т-и В-лимфоцитов [6,[10][11][12][13]. Разработан новый класс таргетных препаратов, представляющих собой химически синтезированные малые молекулы, ингибирующие тирозинкиназы, прежде всего Janus-киназы (JAK), которые через соответствующие трансмембранные рецепторы передают сигналы от цитокинов к ядерным генам-мишеням [6,[14][15][16] недостаточной эффективностью или переносимостью) на препарат с другой направленностью действия.…”

Section: The Development Of Rheumatology At the Stage Of Formation Ofunclassified

The development of rheumatology at the stage of formation of a new technological paradigm

Бекетова¹

2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Section: The Development Of Rheumatology At the Stage Of Formation Ofunclassified

The development of rheumatology at the stage of formation of a new technological paradigm

Бекетова¹

2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Debatable aspects of systemic angiitis and autoinfl ammatory diseases

Шилкина

Dryazhenkova

Yunonin

et al. 2021

jour

View full text Add to dashboard Cite

The new data about immune-infl ammatory rheumatic diseases pathogenesis with the participation of the processes of autoimmunity and autoinfl ammation attract attention to the heterogeneity of systemic angiitis, their nomenclature, classifi cation, pathogenesis and the approaches to the therapy. Recommendations of the second International Chapel Hill Consensus Conference (CHCC2012) and EULAR recommendation (2016, 2018) regarding diagnostics and treatment of SA are discussed. The data of 141 patients with various forms of SA and 18 patients with the diseases, which relate to the group of autoinfl ammatory processes as well as the retrospective analysis of 130 patients with the hyperimmunoglobulinemia E are given.

show abstract

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

Karateev¹,

Polishchuk²,

Potapova³

et al. 2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition of patients with rheumatoid arthritis (RA), taking the patients reported outcomes, as well as the incidence of COVID-19 in these patients.Materials and methods. A telephone survey was conducted of 254 patients with RA (average age – 49.8±13.7 years; 64.4% of patients are positive for rheumatoid factor; women – 83.5%; DAS28 score – 5.4±1.6 points), who in the period from January 2020 to June 2021 were prescribed bDMARDs or iJAK for the first time: 148 (58.3%) – rituximab; 57 (22.4%) – tumor necrosis factor α inhibitors; 20 (7.9%) – iJAK; 17 (6.7%) – interleukin 6 inhibitors; 12 (4.7%) – abatacept.Results. At the time of the survey, 204 (80.3%) patients continued taking prescribed medications. The main reason for the interruption of treatment was administrative problems. Synthetic DMARDs (mainly methotrexate and leflunomide) were received by 68.0%, glucocorticoids – 45.3%, nonsteroidal anti-inflammatory drugs – 44.5% of respondents. Among patients treated with bDMARDs or iJAK, 68.1% noted «the state of symptoms acceptable to the patient», the absence of frequent joint pain – 65.3%, the absence of increased fatigue – 14.3%. The incidence of COVID-19 and hospitalization associated with this disease did not differ in individuals who continued and stopped using bDMARDs or iJAK: 41.2% and 44.6%, 13.7% and 14.0%, respectively (p=0.80884). There were no statistically significant differences in the incidence of COVID-19 and hospitalization associated with this disease in patients taking various bDMARDs or iJAK.Conclusion. Despite the COVID-19 pandemic, rituximab remains one of the most popular bDMARDs. About a third of patients receiving bDMARDs or iJAK are not satisfied with their condition. More than 40% of patients who received these drugs suffered COVID-19; 14.0% required hospitalization.

show abstract

Rituximab and other anti-B-cell agents in immune-mediated inflammatory rheumatic diseases

Cited by 3 publications

References 73 publications

The development of rheumatology at the stage of formation of a new technological paradigm

The development of rheumatology at the stage of formation of a new technological paradigm

Debatable aspects of systemic angiitis and autoinfl ammatory diseases

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients

Contact Info

Product

Resources

About